Screening for Metastatic Osteosarcoma Biomarkers with a DNA Microarray
Screening for Metastatic Osteosarcoma Biomarkers with a DNA Microarray
复制标题
使用 DNA 微阵列筛选转移性骨肉瘤生物标志物
DOI：
10.7314/apjcp.2014.15.4.1817
复制
发表时间：
2014-01-01
影响因子：
--
通讯作者：
Xiao, Tao
中科院分区：
文献类型：
--
作者：
Diao, Chun-Yu;Guo, Hong-Bing;Xiao, Tao
目的：应用DNA微阵列技术筛选转移性骨肉瘤(OS)的可能生物标志物。方法：从基因表达数据库GSE49003下载基因表达谱GSE49003，包括6个来自转移性和非转移性OS患者的基因芯片。R包被用来筛选和识别转移性和非转移性OS患者之间的差异表达基因(DEG)。然后比较两组中DEGS的表达，并将其分为上调和下调两组，然后使用David系统进行功能丰富分析。随后，我们借助WebGestalt软件构建了miRNA-DEG调控网络。结果：共筛选出323个基因，其中上调134个，下调189个。上调的DEGS在14个亚类中丰富，最显著的是在细胞骨架组织中，而下调的DEGS在13个亚类中普遍存在，尤其是伤口愈合。此外，我们还发现了两个与OS转移密切相关的miRNAs(miR-202和miR-9)及其相关基因CALD1和STX1A。结论：MIR-202和miR-9是影响OS转移的潜在关键因素，CALD1和STX1A可能是治疗OS转移的有利靶点。然而，还需要进一步的实验研究来证实我们的结果。
Objective: The aim of this study was to screen for possible biomarkers of metastatic osteosarcoma (OS) using a DNA microarray. Methods: We downloaded the gene expression profile GSE49003 from Gene Expression Omnibus database, which included 6 gene chips from metastatic and 6 from non-metastatic OS patients. The R package was used to screen and identify differentially expressed genes (DEGs) between metastatic and non-metastatic OS patients. Then we compared the expression of DEGs in the two groups and sub-grouped into up-regulated and down-regulated, followed by functional enrichment analysis using the DAVID system. Subsequently, we constructed an miRNA-DEG regulatory network with the help of WebGestalt software. Results: A total of 323 DEGs, including 134 up-regulated and 189 down-regulated, were screened out. The up-regulated DEGs were enriched in 14 subcategories and most significantly in cytoskeleton organization, while the down-regulated DEGs were prevalent in 13 subcategories, especially wound healing. In addition, we identified two important miRNAs (miR-202 and miR-9) pivotal for OS metastasis, and their relevant genes, CALD1 and STX1A. Conclusions: MiR-202 and miR-9 are potential key factors affecting the metastasis of OS and CALD1 and STX1A may be possible targets beneficial for the treatment of metastatic OS. However, further experimental studies are needed to confirm our results.